



Attach #6

(2-92)

Sheet 1 of 1

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)
3935USApplication Number
09/356,575

Applicant Fallaux et al.

Filing Date July 19, 1999

Group Art Unit
1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mm	4,405,712	09/20/83	Vande Woude et al.	—	—	
mm	4,497,796	02/05/85	Salser et al.	—	—	
mm	4,727,028	02/23/88	Sant'erre et al.	—	—	
mm	4,740,463	04/26/88	Weinberg et al.	—	—	
mm	5,190,931	03/02/93	Inouye	—	—	
mm	5,208,149	05/04/93	Inouye	—	—	
mm	5,518,913	05/21/96	Massie et al.	—	—	
mm	5,837,511	11/17/98	Falck-Pedersen et al.	—	—	
mm	5,994,106	11/30/99	Kovesdi et al.	—	—	
mm	5,994,128	11/30/99	Fallaux et al.	—	—	
mm	6,033,908	03/07/00	Bout et al.	—	—	
mm	6,040,174	03/21/00	Imler et al.	—	—	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
mm	2,053,187	04/11/93	Canada	—	—		
mm	WO 94/28152	12/08/94	PCT	—	—		
x mm	2 707 664	01/20/95	France	—	—		X
mm	WO 95/02697	01/26/95	PCT	—	—		
mm	CA 2117668	09/10/95	Canada	—	—		
mm	AU-A-28533/95	03/21/96	Australia	—	—		

EXAMINER

DATE CONSIDERED

10-28-00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 3935US		Application Number To be assigned 09/36575	
				Applicant Fallaux et al.			
				Filing Date July 19, 1999		Group Art Unit To be assigned 1633	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>mw</i>	5,378,618	01/03/95	Sternberg et al.	—	—	
<i>mw</i>	5,545,522	08/13/96	Van Gelder et al.	—	—	
<i>mw</i>	5,652,224	07/29/97	Wilson et al.	—	—	
<i>mw</i>	5,670,488	09/23/97	Gregory et al.	—	—	
<i>mw</i>	5,707,618	01/13/98	Armentano et al.	✓	—	
<i>mw</i>	5,753,500	05/19/98	Shenk et al.	—	—	

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>mw</i>	WO 94/23582	10/27/94	PCT	—	—	X	
<i>mw</i>	WO 94/26914	11/24/94	PCT	—	—	X	
<i>mw</i>	WO 94/28152	12/08/94	PCT	—	—	X	
<i>mw</i>	WO 95/00655	01/05/95	PCT	—	—	X	
<i>mw</i>	WO 95/02097	01/06/95	PCT	—	—	X	
<i>mw</i>	95201611.1	06/15/95	EP	—	—	X	
<i>mw</i>	95201728.3	06/26/95	EP	—	—	X	
<i>mw</i>	WO 95/27071	10/12/95	PCT	—	—	X	
<i>mw</i>	WO 96/16676	06/06/96	PCT	—	—	X	

OTHER DOCUMENTS		(Including Author, Title, Date, Pertinent Pages, Etc.)
<i>mw</i>		Amalfitano et al., "Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors", <u>Proc. Natl. Acad. Sci. USA</u> , 93:3352-3356, April 1996.
<i>mw</i>		Amalfitano et al., "Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy", <u>Gene Therapy</u> , 4:258-263, 1997.
<i>mw</i>		Armentano et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion", <u>Human Gene Therapy</u> , 6:1343-1353, October 1995.
<i>mw</i>		Brough et al., "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4", <u>Journal of Virology</u> , 70(9):6497-6501, September 1996.
<i>mw</i>		Brough et al., "Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein", <u>Virology</u> , 190:624-634, 1992.
<i>mw</i>		Brough et al., "Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4; <u>Abstract Book CSH Conference On Gene Therapy</u> , 42, 1996.

EXAMINER <i>Mw</i>	DATE CONSIDERED 4.1.00
--------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)
3935US

Application Number

To be assigned

Applicant Fallaux et al.

09/35655

Filing Date July 19, 1999

Group Art Unit To be
assigned 1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
mu	WO 96/18418	06/20/96	PCT	—	—	X	
mu	WO 96/33280	10/24/96	PCT	—	—	X	
mu	WO 96/40955	12/19/96	PCT	—	—	X	
mu	WO 97/00326	01/03/97	PCT	—	—	X	
	WO 97/00847	01/08/97	PCT			X	
	WO 97/04110	02/06/97	PCT			X	
	WO 97/05255	02/13/97	PCT			X	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

mu	•	Caravokyri et al., "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5", <u>Journal of Virology</u> , 69(11):6627-6633, November 1995.
mu	•	Fallaux et al., "Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors", <u>Human Gene Therapy</u> , 7:215-222, 1996.
mu	•	Fisher et al., "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis", <u>Virology</u> , 217:11-22, 1996.
mu	•	Gao et al., "Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy", <u>Journal of Virology</u> , 70(12):8934-8943, December 1996.
mu	•	Gorziglia et al., "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy", <u>Journal of Virology</u> , 70(6):4173-4178, June 1996.
mu	•	Hardy et al., "Construction of Adenovirus Vectors through Cre-lox Recombination", <u>Journal of Virology</u> , 71(3):1842-1849, March 1997.
mu	•	Hehir et al., "Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence", <u>Journal of Virology</u> , 70(12):8459-8467, December 1996.

EXAMINER

mu

DATE CONSIDERED

4.1.00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 3935US		Application Number To be assigned 09/356,575	
				Applicant Fallaux et al.		Filing Date July 19, 1999	
				Group Art Unit To be assigned 1633			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS		(Including Author, Title, Date, Pertinent Pages, Etc.)
	•	Imler et al., "Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors", <u>Gene Therapy</u> , 3:75-84, 1996.
	•	Kornberg, Arthur, "DNA Replication", W.H. Freeman and Company, San Francisco, 8 pages.
	•	Krougliak et al., "Development of Cell Lines Capable of Complementation E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants", <u>Human Gene Therapy</u> , 6:1575-1586, December 1995.
	•	Lieber et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo", <u>Journal of Virology</u> , 70:8944-8960, December 1996.
	•	Ngo et al., "in The Protein Folding Problem and Tertiary Structure Prediction", Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, 1994.
	•	Sabatie et al., "Process Development for the Production of Second Generation Adenovirus Vectors for Gene Transfer in Clinical Protocols", <u>Abstract Book 14th Meeting on Animal Cell Technology</u> , BI-3, 1996.
	•	Schaack et al., "Adenovirus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines", <u>Journal of Virology</u> , 69(7):4079-4085, July 1995.
	•	Vanhaesebroeck et al., <u>Virology</u> , 176(2), pp. 362-368, June 1990.
	•	Wang et al., "A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions", <u>Gene Therapy</u> , 2:775-783, 1995.
	•	Yeh et al., "Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit", <u>Journal of Virology</u> , 70(1):559-565, January 1996.
	•	Zhou et al., "Development of a Complementation Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted", <u>Journal of Virology</u> , 70(1):7030-7038, October 1996.

EXAMINER	DATE CONSIDERED 4.1.00
----------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.